全文获取类型
收费全文 | 12253篇 |
免费 | 1106篇 |
国内免费 | 295篇 |
专业分类
耳鼻咽喉 | 97篇 |
儿科学 | 170篇 |
妇产科学 | 362篇 |
基础医学 | 306篇 |
口腔科学 | 65篇 |
临床医学 | 1209篇 |
内科学 | 1159篇 |
皮肤病学 | 31篇 |
神经病学 | 253篇 |
特种医学 | 273篇 |
外国民族医学 | 1篇 |
外科学 | 1041篇 |
综合类 | 1639篇 |
预防医学 | 422篇 |
眼科学 | 41篇 |
药学 | 1376篇 |
10篇 | |
中国医学 | 371篇 |
肿瘤学 | 4828篇 |
出版年
2024年 | 19篇 |
2023年 | 103篇 |
2022年 | 305篇 |
2021年 | 419篇 |
2020年 | 356篇 |
2019年 | 330篇 |
2018年 | 394篇 |
2017年 | 419篇 |
2016年 | 457篇 |
2015年 | 441篇 |
2014年 | 979篇 |
2013年 | 832篇 |
2012年 | 846篇 |
2011年 | 967篇 |
2010年 | 772篇 |
2009年 | 801篇 |
2008年 | 748篇 |
2007年 | 685篇 |
2006年 | 606篇 |
2005年 | 457篇 |
2004年 | 338篇 |
2003年 | 352篇 |
2002年 | 254篇 |
2001年 | 283篇 |
2000年 | 235篇 |
1999年 | 217篇 |
1998年 | 144篇 |
1997年 | 127篇 |
1996年 | 107篇 |
1995年 | 123篇 |
1994年 | 71篇 |
1993年 | 75篇 |
1992年 | 40篇 |
1991年 | 42篇 |
1990年 | 32篇 |
1989年 | 21篇 |
1988年 | 24篇 |
1987年 | 22篇 |
1986年 | 19篇 |
1985年 | 39篇 |
1984年 | 33篇 |
1983年 | 17篇 |
1982年 | 24篇 |
1981年 | 17篇 |
1980年 | 22篇 |
1979年 | 26篇 |
1978年 | 7篇 |
1977年 | 5篇 |
1976年 | 2篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
71.
本文应用平消胶囊配合化学药物治疗52例晚期肺腺癌。全组CR2例,PR25例,总有效率为51.9%,且73.0%的患者症状改善,75.0%的患者功能状态得到改善,1年生存率为36.5%。结果表明平消胶囊与化学药物并用可以提高晚期肺腺癌的治疗效果,改善患者的生存质量。平消胶囊是治疗晚期肺腺癌的有效中成药之一。 相似文献
72.
《Journal of microbiology, immunology, and infection》2023,56(2):392-399
IntroductionNontuberculous mycobacteria (NTM) may be present in the respiratory tract of patients with lung cancer. We investigated the association of pulmonary NTM with the clinical features and outcomes of patients with lung cancer.MethodsBetween 2015 and 2019, the data of patients diagnosed with lung cancer at a medical center in northern Taiwan were analyzed. Patients whose respiratory specimens were culture-positive for NTM were identified (NTM group). For each patient in the NTM group, a matched control was selected (control group). The survival of the two groups was compared using the Kaplan–Meier method and Cox proportional hazards regression analysis.ResultsAmong 8718 patients with lung cancer, 5418 (62.1%) underwent a sputum mycobacterial culture. At least one NTM species was isolated from 138 (2.5%) patients. The median age was 72 years (range: 64–80). In the NTM group, 19.8% fulfilled both the microbiological and radiographic criteria for the diagnosis of NTM lung disease. Compared with the control group, the NTM group exhibited a lower body mass index (22.4 vs. 23.6, p = 0.025) and a higher prevalence of structural lung disease (38.9% vs. 22.2%, p = 0.004). The two-year survival was not significantly different between the two groups (hazard ratio [HR]: 1.110; 95% confidence interval [CI]: 0.702–1.754, p = 0.656). In patients receiving chemotherapy, pulmonary NTM was associated with worse survival (HR: 2.497, 95% CI: 1.262–4.943, p = 0.009).ConclusionsExcept in patients receiving chemotherapy, pulmonary NTM may not be clinically relevant in patients with lung cancer. 相似文献
73.
Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma 总被引:3,自引:0,他引:3
Recombinant human erythropoietin (rHu-EPO) is an effective growth factor for erythroid progenitor cells in anemia provoked by several conditions, including bone marrow tumors such as multiple myeloma (MM). We studied a group of 54 patients with MM undergoing second-induction chemotherapy. Thirty of them were randomly assigned to receive rHu-EPO at an initial dosage of 150 units/kg body weight three times a week, increased to 300 units/kg from the sixth week to the end of the 24-week study. Hemoglobin (Hb) levels increased in 77.7% of these patients by the eighth week. In addition, five transfusion-dependent patients in treatment with the VMCP protocol completed the trial without requiring blood supplement after the third month, whereas seven control patients required frequent supplements. Monthly assessment of hematologic parameters demonstrated the ability of rHu-EPO to increase reticulocyte counts, whereas five patients became resistant to the second-induction chemotherapy in apparent concurrence with their rHu-EPO therapy. The response to rHu-EPO in four of the five MM patients receiving cytotoxic protocols combined with -interferon (-IFN) included an increase of serum IgM after the third month. This effect was not demonstrable in any other group, including three rHu-EPO-untreated patients undergoing -IFN + VMCP combined therapy, as well as rHu-EPO-treated patients not receiving a-IFN. Our data suggest that -IFN plus rHu-EPO treatment in MM patients is effective in restoring normal B cell function. These results may reflect in vivo the modulation of normal human B cells and lymphoblasts by rHu-EPO observed in vitro. 相似文献
74.
Improved survival in young women with breast cancer 总被引:3,自引:0,他引:3
Dr. Benjamin O. Anderson MD Ruby T. Senie PhD John T. Vetto MD George Y. Wong PhD Beryl McCormick MD Patrick I. Borgen MD 《Annals of surgical oncology》1995,2(5):407-415
Background: Young age has been hypothesized to be an adverse prognostic factor for women with breast cancer. This association, based on historical data, may not reflect recent advances in breast cancer management.
Methods: A retrospective study was conducted of all women age 30 or younger who underwent definitive operation at our institution for primary operable breast carcinoma during one of two consecutive 20-year periods (1950–1969 or 1970–1989). All cancers were restaged according to current staging criteria. Actuarial survival and recurrence-free survival rates from the two patient eras were compared with each other and with published statistics for older breast cancer patients.
Results: Eligibility criteria were met by 81 women from the 1950–1969 era and 146 women from the 1970–1989 era. Histologic diagnoses, tumor sizes, incidence of axillary nodal metastases, number of positive nodes, and American Joint Committee on Cancer stage at presentation were similarly distributed in the two eras. Despite these similarities, improved survival (p=0.009) was observed in the later era. Local recurrences were also more common (p<0.05) in the later era in association with less extensive resections. These local recurrences had an adverse impact on recurrence-free survival in the later era, but no concomitant decrease in overall survival was observed. Node-positive patients who received chemotherapy demonstrated a trend toward improved survival (p=0.06) compared with node-positive patients who did not. Survival for patients in the later era was similar to that for older women as reported in other published series.
Conclusions: The stage of presentation of breast cancer in women 30 years or younger appears unchanged from prior decades, but survival has improved in association with the use of less extensive surgical resections and the introduction of cytotoxic chemotherapy. With current treatment, primary operable breast cancer in young women appears to have a similar prognosis to breast cancer in older women.Results of this study were presented at the 47th Annual Cancer Symposium of The Society of Surgical Oncology, Houston, Texas, March 17–20, 1994, and was judged Best Clinical Paper in the Resident/Fellow Essay Contest. 相似文献
75.
报导了35例选择性 支气管动脉化疗灌注治疗原发性肺癌、35例共进行支气管动脉灌注67例次,近期追踪观察有效率为88.6%,同时对本法的具体实施步骤,药物灌注的理论基础、支气管动脉解剖变异及预防严重并发症的措施,作了具体分析和探讨。 相似文献
76.
观察粒系集落刺激因子(G-CSF)在恶性淋巴瘤治疗中的作用。对52例恶性淋巴瘤患者随机分为二组,27例接受化疗加G-CSF治疗,25例单独应用化疗.并对60岁以上老年患者另行分组进行研究。结果显示.G-CSF治疗组在白细胞和中性粒细胞降低持续时间、患者发热持续时间、化疗总疗程后延病例数及化疗总剂量减少病例数等方面均较对照组显著减少(P<0.05~0.001)。但临床缓解率和2年生存率两组无明显差异。对60岁以上老年患者,G-CSF治疗可显著加快白细胞和中性粒细胞数的恢复.并明显减少化疗总疗程延及总剂量减少病例数。以上结果提示.G-CSF可有效恢复化疗所致的曰细胞和中性粒细胞减少,确保化疗能足量按时完成.将对恶性淋巴瘤的治疗尤其是老年患者的治疗产生有益作用。 相似文献
77.
The management of rectal cancer presents substantial challenges. Patients with T3 and/or node-positive rectal cancers are at high risk for local failure and distant metastases (DM). Adjuvant radiation has been shown to decrease local recurrence (LR) rates; however, this local therapy has not been demonstrated to improve survival when compared to surgery alone. In several prospective randomized trials adjuvant chemoradiation with 5-fluorouracil-(5-FU)-based chemotherapy improved LR rates, DM rates, and overall survival (OS). The optimal chemotherapeutic regimen has not been determined; however, studies comparing standard IV bolus 5-FU administration with continuous infusion (CI) 5-FU demonstrated that CI administration was superior. Preoperative therapy has potential advantages over adjuvant therapy such as less acute bowel toxicity and improved sphincter preservation. Preoperative chemoradiation has been shown in several studies to improve LR rates and OS when compared to surgery alone. Our current approach to patients with resectable T3 or N1 cancer in the distal two-thirds of the rectum on preoperative staging is preoperative chemoradiation with planned postoperative chemotherapy. This regimen offers the best chance for local control and disease-free survival while potentially downstaging the tumor and improving sphincter preservation. 相似文献
78.
Multidisciplinary management of metastatic colorectal cancer 总被引:4,自引:0,他引:4
When colorectal cancer metastasizes to distant organs, usually multiple sites are involved and treatment consists primarily of systemic chemotherapy and supportive care. Chemotherapeutic agents effective against metastatic colorectal cancer include 5-fluorouracil, often used in combination with leucovorin or methotrexate, and irinotecan (CPT-11). Median survival with optimal chemotherapy regimens ranges from 10 to 15 months. Less frequently, colorectal cancer metastasizes only to the liver or lung. In a minority of these cases, surgical resection can be performed and results in a median survival of 28-46 months for hepatic resections and 24-25 months for pulmonary resections. Five-year survival rates range from 24 to 38% and 21 to 44% for hepatic and pulmonary resections, respectively. For isolated liver metastases that are not surgically resectable, other regional therapies that can be considered are hepatic cryosurgery, radiofrequency ablation, and hepatic arterial infusion chemotherapy. Median survival following cryosurgery is between 26 and 30 months, while median survival following radiofrequency ablation has not been established in large series. Hepatic arterial infusion chemotherapy, especially with newer combination drug regimens, may increase survival in patients with isolated liver metastases compared to systemic chemotherapy, but this must be confirmed in randomized, prospective trials. Colorectal cancer metastases to the brain can be treated with radiation therapy or surgical resection, but median survival with treatment is less than one year. 相似文献
79.
M. Caruso-Nicoletti M. Mancuso G. Spadaro S. P. Dibenedetto A. DiCataldo G. Schiliró 《European journal of pediatrics》1993,152(9):730-733
Growth impairment and growth hormone (GH) deficiency have been reported in children treated for acute lymphoblastic leukaemia (ALL). We have studied growth and GH secretion in a group of 50 patients, affected by ALL, during a 2- to 5-year period after diagnosis, and in 12 long-term-survivors. We observed a significant decrease in growth velocity during the 1st year (in particular during the first 6 months) of therapy and a catch-up growth after the end of therapy. Longterm survivors did not exhibit a significant reduction of height standard deviation score (SDS), as compared to height SDS at diagnosis. None of the patients showed GH deficiency. Our data indicate that chemotherapy significantly affects growth of patients treated for ALL, whereas radiotherapy-at the doses used in this study-does not induce GH deficiency, at least not within 9 years after diagnosis. 相似文献
80.
Amerigo Boiardi Antonio Silvani Sergio Valentini Andrea Salmaggi Antonio Allegranza Giovanni Broggi 《Journal of neurology》1993,241(2):96-100
Non-Hodgkin's lymphoma of the central nervous system (NHL-CNS) is thought to account for about 1 % of primary brain tumours. Radiation therapy has mainly been applied to treat cerebral lymphoma, but the low cure rate and the lack of enduring response have stimulated the search for alternatives. With the aim of postponing radiotherapy as long as possible, we tested the efficacy of a M-BACOD schedule administered immediately after histological diagnosis in 14 patients. After two M-BACOD courses 10 (71%) patients displayed an objective response (i.e. were apparently tumour-free when examined by CT). In 6 (60%) M-BACOD-responsive patients, radiotherapy was delayed for 5 months (without recurrences after a follow-up ranging from 9 to 18 months). Moreover, in 3 M-BACOD-responsive patients, no recurrence took place (even without radiotherapy) after a follow-up of 6–12 months. We conclude that radiation can be postponed after chemotherapy or delayed until tumor recurrence.This paper was presented at the 3rd Meeting of the European Neurological Society, Lausanne, 27 June–1 July, 1992 相似文献